Premium
Migraine Prophylaxis with Lisuride Hydrogen Maleate‐A Double Blind Study of Lisuride Versus Placebo
Author(s) -
Somerville Brian W.,
Herrmann Werner M.
Publication year - 1978
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1978.hed1802075.x
Subject(s) - lisuride , migraine , placebo , anesthesia , methysergide , medicine , double blind , antagonist , dopamine agonist , agonist , receptor , alternative medicine , pathology
SYNOPSIS This paper reports the results of a double‐blind clinical trial of the antiserotonin compound Lisuride hydrogen maleate (LHM) in the prophylaxis of frequent and severe migraine. The study was conducted over a minimum period of three months. When judged according to reduction in frequency of attacks, LHM emerged significantly superior to placebo (p<0.05), though a higher rate of side effects was noted in the active treatment group. A high rate of placebo response (in keeping with other similar trials) was observed.It is concluded that LHM is significantly superior to placebo as a migraine prophylactic and its relative freedom from serious side effects suggests a useful role for the drug as an alternative to methysergide.